Short answer
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026.
Tvardi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026
- Business highlights included alongside quarterly financial results
- Exhibit 99.1 contains the detailed financial metrics and operating update
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $6.1M, or $(0.48) per share, versus $5.5M and $(0.59) year over year
- R&D expense $4.5M, up from $3.6M, reflecting higher TTI-101 clinical costs
- Cash and equivalents $22.3M versus $30.8M at December 31, 2025, with runway into Q3 2027
- TTI-101 HCC topline data expected early Q1 2027, a key near-term clinical catalyst
- TTI-109 UC trial initiation targeted for 2027, contingent on IND clearance and additional funding
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tvardi Therapeutics, Inc. 8-K filings
Get the next TVRD 8-K as it lands
Follow TVRD for push alerts, or ask the research agent what this filing means.